Search Results - "Waldschmidt, Dirk‐Thomas"

Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort by Finkelmeier, Fabian, Scheiner, Bernhard, Leyh, Catherine, Best, Jan, Fründt, Thorben Wilhelm, Czauderna, Carolin, Beutel, Alica, Bettinger, Dominik, Weiß, Johannes, Meischl, Tobias, Kütting, Fabian, Waldschmidt, Dirk-Thomas, Radu, Pompilia, Schultheiß, Michael, Peiffer, Kai-Henrik, Ettrich, Thomas J., Weinmann, Arndt, Wege, Henning, Venerito, Marino, Dufour, Jean-Francois, Lange, Christian M., Pinter, Matthias, Waidmann, Oliver

“…Background and Aims: The multikinase inhibitor cabozantinib has been approved for hepatocellular carcinoma (HCC) previously treated with sorafenib. We report…”
Get full text

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score by Scheiner, Bernhard, Pomej, Katharina, Kirstein, Martha M., Hucke, Florian, Finkelmeier, Fabian, Waidmann, Oliver, Himmelsbach, Vera, Schulze, Kornelius, von Felden, Johann, Fründt, Thorben W., Stadler, Marc, Heinzl, Harald, Shmanko, Kateryna, Spahn, Stephan, Radu, Pompilia, Siebenhüner, Alexander R., Mertens, Joachim C., Rahbari, Nuh N., Kütting, Fabian, Waldschmidt, Dirk-Thomas, Ebert, Matthias P., Teufel, Andreas, De Dosso, Sara, Pinato, David J., Pressiani, Tiziana, Meischl, Tobias, Balcar, Lorenz, Müller, Christian, Mandorfer, Mattias, Reiberger, Thomas, Trauner, Michael, Personeni, Nicola, Rimassa, Lorenza, Bitzer, Michael, Trojan, Jörg, Weinmann, Arndt, Wege, Henning, Dufour, Jean-François, Peck-Radosavljevic, Markus, Vogel, Arndt, Pinter, Matthias

“…Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC)…”
Get full text

Sequence therapy in metastatic pancreatic cancer by Waidmann, Oliver, Pelzer, Uwe, Boeck, Stefan, Waldschmidt, Dirk-Thomas

“…Pancreatic cancer is one of the most lethal cancer diseases. For years, gemcitabine has been the standard of care and the only therapeutic option in patients…”
Get more information

Efficacy, safety and differential outcomes of immune‐chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort by Mitzlaff, Katharina, Kirstein, Martha M., Müller, Christian, Venerito, Marino, Olkus, Alexander, Dill, Michael T., Weinmann, Arndt, Kocheise, Lorenz, Busch, Alina, Schulze, Kornelius, Allo, Gabriel, Waldschmidt, Dirk‐Thomas, Barsch, Maryam, Bengsch, Bertram, Quante, Michael, Gonzalez‐Carmona, Maria A., Himmelsbach, Vera, Finkelmeier, Fabian, Kloeckner, Roman, Schirmacher, Peter, Marquardt, Jens U., Zimpel, Carolin

“…Background Combined Immuno‐chemotherapy consisting of gemcitabine, cisplatin and the programmed death‐ligand one inhibitor durvalumab (GCD) is the new standard…”
Get full text

Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report by Reutter, Theresa, Fassunke, Jana, Püsken, Michael, Weber, Jan-Phillip, Binot, Elke, Eisert, Anna, Fischer, Rieke, Nogova, Lucia, Riedel, Richard, Schaufler, Diana, Scharpenseel, Heather, Scheffler, Matthias, Schulz, Holger, Waldschmidt, Dirk-Thomas, Zander, Thomas, Merkelbach-Bruse, Sabine, Schirmacher, Peter, Büttner, Reinhard, Wolf, Jürgen, Michels, Sebastian

Get more information

Results of a phase Ib study of regorafenib (REG) 80 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC) by Kim, Richard D., Harris, William P., Sung, Max W., Waldschmidt, Dirk Thomas, Cabrera, Roniel, Mueller, Udo, Menezes, Flavia, Ishida, Tatiane, Galle, Peter R., El-Khoueiry, Anthony B.

“…Abstract only 323 Background: In a phase Ib study, REG 120 mg/day plus PEMBRO for first-line treatment of advanced HCC showed no unexpected safety signals and…”
Get full text

FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC) by Westphalen, Benedikt, Gaska, Tobias, Reichert, Maximilian, Quante, Michael, Oettle, Helmut, Waldschmidt, Dirk Thomas, Schlenska-Lange, Anke, Angermeier, Stefan, Fischer von Weikersthal, Ludwig, Bohle, Wolfram, Vehling-Kaiser, Ursula, Stahler, Arndt, Kanzler, Stephan, Lamberti, Christof, Pelzer, Uwe, Sinn, Marianne, Blau, Wolfgang, Boeck, Stefan Hubert, Held, Swantje, Heinemann, Volker

“…4021 Background: The optimal first-line regimen in the treatment of mPDAC remains unknown. Recent data demonstrated superiority of 5-FU/liposomal…”
Get full text

Validation of the CRAFITY score in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab by Scheiner, Bernhard, Sartoris, Riccardo, D’Alessio, Antonio, Fulgenzi, Claudia, Pomej, Katharina, Balcar, Lorenz, Bouattour, Mohamed, Sidali, Sabrina, Himmelsbach, Vera, Finkelmeier, Fabian, Schulze, Kornelius, von Felden, Johann, Hucke, Florian, Shmanko, Kateryna, Siebenhüner, Alexander, Mertens, Joachim C., De Dosso, Sara, Ebert, Matthias, Teufel, Andreas, Waldschmidt, Dirk-Thomas, Radu, Iuliana Pompilia, Krall, Anja, Trauner, Michael, Dufour, Jean-François, Wege, Henning, Weinmann, Arndt, Trojan, Jörg, Stauber, Rudolf E., Peck-Radosavljevic, Markus, Hsu, Wei-Fan, Vogel, Arndt, Ronot, Maxime, Pinato, David J., Pinter, Matthias

Get full text

FRI-273 - Validation of the CRAFITY score in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab by Scheiner, Bernhard, Sartoris, Riccardo, D’Alessio, Antonio, Fulgenzi, Claudia, Pomej, Katharina, Balcar, Lorenz, Bouattour, Mohamed, Sidali, Sabrina, Himmelsbach, Vera, Finkelmeier, Fabian, Schulze, Kornelius, von Felden, Johann, Hucke, Florian, Shmanko, Kateryna, Siebenhüner, Alexander, Mertens, Joachim C., De Dosso, Sara, Ebert, Matthias, Teufel, Andreas, Waldschmidt, Dirk-Thomas, Radu, Iuliana Pompilia, Krall, Anja, Trauner, Michael, Dufour, Jean-François, Wege, Henning, Weinmann, Arndt, Trojan, Jörg, Stauber, Rudolf E., Peck-Radosavljevic, Markus, Hsu, Wei-Fan, Vogel, Arndt, Ronot, Maxime, Pinato, David J., Pinter, Matthias

Get full text

OS-079-YI Development and validation of the CABLE score to estimate individual prognosis of patients with hepatocellular carcinoma treated with 1L atezolizumab and bevacizumab by Gairing, Simon Johannes, Mildenberger, Philipp, Gile, Jennifer, Artusa, Fabian, Scheiner, Bernhard, Leyh, Catherine, Lieb, Sabine, Sinner, Friedrich, Jörg, Vincent, Fruendt, Thorben, Himmelsbach, Vera, Abedin, Nada, Sahin, Cennet, Boettcher, Katrin, Schuhbaur, Jasmin, Labuhn, Simon, Korolewicz, James, Fulgenzi, Claudia, D'Alessio, Antonio, Zanuso, Valentina, Hucke, Florian, Röhlen, Natascha, Khaled, Najib Ben, Ramadori, Eleonora, Müller, Lukas, Weinmann, Arndt, Kloeckner, Roman, Galle, Peter R., Tran, Nguyen H., Venkatesh, Sudhakar, Teufel, Andreas, de Toni, Enrico, Waldschmidt, Dirk-Thomas, Marquardt, Jens U., Bettinger, Dominik, Peck-Radosavljevic, Markus, Geier, Andreas, Reiter, Florian P, Rimassa, Lorenza, Pinato, David J., Roderburg, Christoph, Ettrich, Thomas, Bitzer, Michael, Scheble, Veit, Ehmer, Ursula, Berres, Marie-Luise, Finkelmeier, Fabian, Gonzalez-Carmona, Maria Angeles, von Felden, Johann, Schulze, Kornelius, Venerito, Marino, van Bömmel, Florian, Jochheim, Leonie, Pinter, Matthias, Mohr, Raphael, Ilyas, Sumera I., Schmidtmann, Irene, Foerster, Friedrich

Get full text

Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement by Javle, Milind M., Roychowdhury, Sameek, Kelley, Robin Kate, Sadeghi, Saeed, Macarulla, Teresa, Waldschmidt, Dirk Thomas, Goyal, Lipika, Borbath, Ivan, El-Khoueiry, Anthony B., Yong, Wei-Peng, Philip, Philip Agop, Bitzer, Michael, Tanasanvimon, Suebpong, Li, Ai, Pande, Amit, Shepherd, Stacie Peacock, Moran, Susan, Abou-Alfa, Ghassan K.

“…Abstract only 265 Background: Treatment options for cholangiocarcinoma (CCA) after progression on first-line gemcitabine-based therapy are limited. Fibroblast…”
Get full text

Cabozantinib in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicenter real-world cohort by Finkelmeier, Fabian, Scheiner, Bernhard, Leyh, Catherine, Best, Jan, Fründt, Thorben Wilhelm, Czauderna, Carolin, Beutel, Alica, Bettinger, Dominik, Weiß, Johannes, Meischl, Tobias, Kuetting, Fabian, Waldschmidt, Dirk Thomas, Schultheiß, Michael, Ettrich, Thomas Jens, Weinmann, Arndt, Wege, Henning, Venerito, Marino, Lange, Christian, Pinter, Matthias, Waidmann, Oliver

“…Abstract only e16668 Background: The multikinase inhibitor cabozantinib has been approved by the European Medicines Agency in November 2018 for hepatocellular…”
Get full text

Implementing a novel method to estimate the "Burden of Therapy" (BOTh) for patients with metastatic pancreatic cancer treated with gemcitabine plus afatinib vs. gemcitabine in the AIO ACCEPT trial by Haas, Michael, Abdul-Ahad, Ayad, Snijder, Robert, Waldschmidt, Dirk Thomas, Stahl, Michael, Reinacher-Schick, Anke C., Freiberg-Richter, Jens, Kaiser, Florian, Kanzler, Stephan, Frickhofen, Norbert, Seufferlein, Thomas, Dechow, Tobias Nicolaas, Mahlberg, Rolf, Malfertheiner, Peter, Illerhaus, Gerald, Kubicka, Stefan, Held, Swantje, Boeck, Stefan Hubert, von Bergwelt-Baildon, Michael, Heinemann, Volker

“…Abstract only e16786 Background: The phase II ACCEPT trial included 119 patients (pts) with histologically proven pancreatic cancer without any previous…”
Get full text

Structured Reporting of Solid and Cystic Pancreatic Lesions in CT and MRI: Consensus-Based Structured Report Templates of the German Society of Radiology (DRG) by Persigehl, Thorsten, Baumhauer, Matthias, Baeßler, Bettina, Beyer, Lukas Philipp, Bludau, Marc, Bruns, Christiane, Bunck, Alexander Christian, Germer, Christoph-Thomas, Grenacher, Lars, Hackländer, Thomas, Haneder, Stefan, Heinrich, Stefan, Heusch, Philipp, Hoffmann, Matthias, Juchems, Markus S, Kröger, Jan Robert, Kotter, Elmar, Layer, Günter, Maintz, David, Menke, Jan, Palmowski, Moritz, Pantelis, Dimitrios, Pinto Dos Santos, Daniel, Popp, Felix Christoph, Schäfer, Nico, Schlemmer, Heinz-Peter, Schreyer, Andreas G, Siedek, Florian, Stippel, Dirk, Völker, Martin, Waldschmidt, Dirk Thomas, Weber, Tim Frederik, von Winterfeld, Moritz, Wybranski, Christian, Zander, Thomas, Wessling, Johannes

“…Radiological reports of pancreatic lesions are currently widely formulated as free texts. However, for optimal characterization, staging and operation…”
Get more information